Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections
AbstractSystemic rheumatic diseases have significant morbidity and mortality, due in large part to concurrent infections. The lung has been reported among the most frequent sites of infection in patients with rheumatic disease, who are susceptible to developing pneumonia sustained both by common pathogens and by opportunistic microorganisms. Patients with rheumatic disease show a peculiar vulnerability to infectious complications. This is due in part to intrinsic disease-related immune dysregulation and in part to the immunosuppressive treatments. Several therapeutic agents have been associated to a wide spectrum of infections, complicating the management of rheumatic diseases. This review discusses the most frequent pulmonary infections encountered in rheumatic diseases, focusing on opportunistic agents, consequent diagnostic challenges and appropriate therapeutic strategies. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Di Franco, M.; Lucchino, B.; Spaziante, M.; Iannuccelli, C.; Valesini, G.; Iaiani, G. Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections. Int. J. Mol. Sci. 2017, 18, 293.
Di Franco M, Lucchino B, Spaziante M, Iannuccelli C, Valesini G, Iaiani G. Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections. International Journal of Molecular Sciences. 2017; 18(2):293.Chicago/Turabian Style
Di Franco, Manuela; Lucchino, Bruno; Spaziante, Martina; Iannuccelli, Cristina; Valesini, Guido; Iaiani, Giancarlo. 2017. "Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections." Int. J. Mol. Sci. 18, no. 2: 293.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.